Powdered lipid nano and microparticles: Production and applications

Recent Patents on Drug Delivery and Formulation

Volumn 5, Issue 3, 2011, Pages 188-200

  Berton, Amandine ^a   Piel, Géraldine ^a   Evrard, Brigitte ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Lipidic excipients; Manufacturing process; Microparticles; Nanoparticles; Pharmaceutical technology; Supercritical fluids

Indexed keywords

LIPOSOME; NANOSPHERE; POLOXAMER; SOLID LIPID NANOPARTICLE;

ARTICLE; BIOCOMPATIBILITY; BIOTECHNOLOGICAL PROCEDURES; CRYOGENIC MICRONIZATION; CRYSTALLIZATION; DEGRADATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG TOLERABILITY; ELECTROSPRAY; GENE THERAPY; MEDICAL RESEARCH; NANOTECHNOLOGY; NEBULIZATION; NONHUMAN; PARTICLE SIZE; PATENT; PHYSICAL CHEMISTRY; PRESSURE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROCESS TECHNOLOGY; PUBLICATION; SPRAY CONGEALING; SPRAY DRYING; SUPERCRITICAL FLUID; TEMPERATURE;

ANIMALS; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EXCIPIENTS; GENE TRANSFER TECHNIQUES; HUMANS; LIPIDS; NANOPARTICLES; PATENTS AS TOPIC; POWDERS;

EID: 80052849387     PISSN: 18722113     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221111797200588     Document Type: Article

References (148)

1. Mehnert W, Mader K. Solid lipid nanoparticles, Production, characterization and applications. Adv Drug Deliv Rev 2001; 47:165-96.
2. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of art. Eur J Pharmaceut Biopharmaceut 2000; 50: 161-177.
3. Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery: II. Drug incorporation and physicochemical characterization. J Microencapsul 1999; 16(2): 205-13.
4. Jaspart S, Piel G, Delattre L, Evrard B. Solid lipid microparticles: formulation, preparation, characterisation, drug release and applications. Expert Opin Drug Deliv 2005; 2 (1):75-87.
5. Ravi KMNV. Nano and microparticles as controlled drug delivery devices. J Pharm Pharmaceut Sci 2000; 3(2): 234-58.
6. Dalpiaz A, Cacciari B, Mezzena M, Strada M, Scalia S. Solid lipid microparticles for the stability enhancement of a dopamine prodrug. J Pharm Sci 2010; 99(11): 4730-7.
7. Sebti T, Amighi K. Preparation and in vitro evaluation of lipidic carriers and fillers for inhalation. Eur J Pharm Biopharm 2006; 63(1): 51-8.
8. Battaglia L, Gallarate M, Cavalli R, Trotta M. Solid lipid nanoparticles produced through a coacervation method. J Microencapsul 2010; 27(1): 78-85.
9. Bondi ML, Craparo EF. Solid lipid nanoparticles for applications in gene therapy: A review of the state of the art. Expert Opin Drug Deliv 2010; 7(1): 7-18.
10. Garcia-Gonzalez CA, Sampaio da Sousa AR, Argemi A, Lopez Periago A, Saurina J, Duarte CM, et al. Production of hybrid lipid- based particles loaded with inorganic nanoparticles and active compounds for prolonged topical release. Int J Pharm 2009; 382(1-2): 296-304.
11. Hitzman CJ, Elmquist WF, Wiedmann TS. Development of a respirable, sustained release microcarrier for 5-fluorouracil II: In vitro and in vivo optimization of lipid coated nanoparticles. J Pharm Sci 2006; 95(5): 1127-43.
12. Hitzman CJ, Elmquist WF, Wattenberg LW, Wiedmann TS. Development of a respirable, sustained release microcarrier for 5- fluorouracil I: In vitro assessment of liposomes, microspheres, and lipid coated nanoparticles. J Pharm Sci 2006; 95(5): 1114-26.
13. Jaspart S, Bertholet P, Piel G, Dogne JM, Delattre L, Evrard B. Solid lipid microparticles as a sustained release system for pulmonary drug delivery. Eur J Pharm Biopharm 2007; 65: 47-56.
14. Mehnert W, Mader K. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev 2001; 47(2-3): 165-96.
15. Passerini N, Qi S, Albertini B, Grassi M, Rodriguez L, Craig DQ. Solid lipid microparticles produced by spray congealing: Influence of the atomizer on microparticle characteristics and mathematical modeling of the drug release. J Pharm Sci 2010; 99(2): 916-31.
16. Trotta M, Cavalli R, Trotta C, Bussano R, Costa L. Electrospray technique for solid lipid-based particle production. Drug Dev Ind Pharm 2010; 36(4): 431-8.
17. Brion M, Jaspart S, Perrone L, Piel G, Evrard B. The supercritical micronization of solid dispersions by Particles from Gas Saturated Solutions using experimental design. J Supercrit Fluids 2009; 51(1): 50-6.
18. Rodriguez, L.C., Cavallari, C., Motta, G. Apparatus and method for preparing solid forms with controlled release of the active ingredient. WO9603979 (1996).
19. Pilcer G, Sebti T, Amighi K. Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation. Pharmaceut Res 2006; 23(5): 931-40.
20. Depreter F, Amighi K. Formulation and in vitro evaluation of highly dispersive insulin dry powder formulations for lung administration. Eur J Pharm Biopharm 2010; 76(3): 454-63.
21. Eldem T, Speiser P, Hincal A. Optimization of spray-dried and congealed lipid micropellets and characterization of their surface morphology by scanning electron microscopy. Pharmaceut Res 1991; 8(1): 47-54.
22. Brasseur S, Amighi K, Moes AJ. Evaluation of solid lipid microparticles for controlled delivery to the pulmonary tract. In: Spa, Belgium 2000; 11.
23. Killeen MJ. Spray drying and spray congealing of pharmaceuticals. Encyclopedia Pharmaceut Technol Edited by Swarbrick J, Boylan JC 2000: 207-21.
24. Poortinga, A.R.J. Method and apparatus for spray drying and powder produced using said method. US2011052786 (2011).
25. Friesen, D.D., Baumann, J.M., Dubose, D.B., Millard, D.L. Spraydrying process. WO2010111132 (2010).
26. Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm 2010; 392(1-2): 1-19.
27. Johnson KA. Preparation of peptide and protein powders for inhalation. Adv Drug Deliv Rev 1997; 26(1): 3-15.
28. Steckel H, Brandes HG. A novel spray-drying technique to produce low density particles for pulmonary delivery. Int J Pharmaceuti 2004; 278(1): 187-95.
29. Van Krimpen, H.R. Spray-drying device WO2011028105 (2011).
30. Bot, A., Dellamary, L., Smith, D., Woods, C.M. Engineered spraydried lipid-based microparticles for cellular targeting. WO0164254 (2001).
31. Del Curto MD, Chicco D, D'Antonio M, Ciolli V, Dannan H, D'Urso S, et al. Lipid microparticles as sustained release system for a GnRH antagonist (Antide). J Control Rel 2003; 89: 297-310.
32. Del Curto, D., Esposito, P. Lipid microparticles by cryogenic micronization. US2004091522 (2004).
33. Savolainen M, Herder J, Khoo C, Lovqvist K, Dahlqvist C, Glad H, Juppo AM. Evaluation of polar lipid-hydrophilic polymer microparticles. Int J Pharmaceut 2003; 262(1-2): 47-62.
34. Savolainen M, Khoo C, Glad H, Dahlqvist C, Juppo AJ. Evaluation of controlled-release polar lipid microparticles. Int J Pharmaceut 2002; 244: 151-61.
35. Albertini B, Mezzena M, Passerini N, Rodriguez L, Scalia S. Evaluation of spray congealing as technique for the preparation of highly loaded solid lipid microparticles containing the sunscreen agent, avobenzone. J Pharm Sci 2009; 98(8): 2759-69.
36. Albertini B, Passerini N, Pattarino F, Rodriguez L. New spray congealing atomizer for the microencapsulation of highly concentrated solid and liquid substances. Eur J Pharm Biopharm 2008; 69(1): 348-357.
37. Maschke A, Becker C, Eyrich D, Kiermaier J, Blunk T, Gopferich A. Development of a spray congealing process for the preparation of insulin-loaded lipid microparticles and characterization thereof. Eur J Pharm Biopharm 2007; 65(2): 175-87.
38. Passerini N, Albertini B, Perissutti B, Rodriguez L. Evaluation of melt granulation and ultrasonic spray congealing as techniques to enhance the dissolution of praziquantel. Int J Pharm 2006; 318(1-2): 92-102.
39. Passerini N, Gavini E, Albertini B, Rassu G, Di Sabatino M, Sanna V, et al. Evaluation of solid lipid microparticles produced by spray congealing for topical application of econazole nitrate. J Pharm Pharmacol 2009; 61(5): 559-67.
40. Passerini N, Perissuti B, Albertini B, Voinovich D, Moneghini M, Rodriguez L. Controlled release of verapamil hydrochloride from waxy microparticles prepared by spray congealing. J Control Release 2003; 88: 263-275.
41. Rodriguez L, Passerini N, Cavallari C, Cini M, Sancin P, Fini A. Description and preliminary evaluation of a new ultrasonic atomizer for spray-congealing processes. Int J Pharmaceut 1999; 183: 133-43.
42. Passerini N, Perissutti B, Moneghini M, Voinovich D, Albertini B, Cavallari C, et al. Characterization of carbamazepine-Gelucire 50/13 microparticles prepared by a spray-congealing process using ultrasounds. J Pharm Sci 2002; 91(3): 699-707.
43. Akiyama Y, Yoshioka M, Horibe H, Hirai S, Kitamori N, Toguchi H. Novel oral controlled-release microspheres using polyglycerol esters of fatty acids. J Control Rel 1993; 26(1): 1-10.
44. Richard, J., Baldascini, H.G., Agostinetto, R., De Angelis, L., Deschamps, F. Solid lipid microcapsules containing growth hormone in the inner solid core WO2009080164 (2009).
45. Richard, J., Fais, F., Baldascini, H. Solid lipid microcapsules containing hGH. WO2010017965 (2010).
46. Faure, A.V.J.F.M., Mertens, R.J.M., Kiekens, F.R.I. Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet. US2011082214 (2011).
47. Petersen, T.S. Process and apparatus for spray drying or spray cooling. US6151798 (2000).
48. Peltonen L, Valo H, Kolakovic R, Laaksonen T, Hirvonen J. Electrospraying, spray drying and related techniques for production and formulation of drug nanoparticles. Exp Opin Drug Deliv 2010; 7(6): 705-719.
49. Rohner TC, Lion N, Girault HH. Electrochemical and theoretical aspects of electrospray ionisation. Phys Chem Chemical Physics 2004; 6(12): 3056-68.
50. Drechsler MD, Obermeier I, Doring Y, Lackner KJ, Modrow S, von Landenberg P. Generation of multifunctional murine monoclonal antibodies specifically directed to the VP1unique region protein of human parvovirus B19. Immunobiology 2008; 213(6): 511-7.
51. Zhang, Y. Preparation of lipid particles. KR20060123170 (2006).
52. Amidi M, Pellikaan HC, de Boer AH, Crommelin DJA, Hennink WE, Jiskoot W. Preparation and physicochemical characterization of supercritically dried insulin-loaded microparticles for pulmonary delivery. Eur J Pharm Biopharm 2007; In Press, Corrected Proof.
53. Bahrami M, Ranjbarian S. Production of micro- and nanocomposite particles by supercritical carbon dioxide. J Supercrit Fluids 2007; 40(2): 263-83.
54. Knez Z, Weidner E. Particles formation and particle design using supercritical fluids. Curr Opin Solid State Mat Sci 2003; 7(4-5): 353-61.
55. Jung J, Perrut M. Particle design using supercritical fluids: Literature and patent survey. J Supercritical Fluids 2001; 20(3):179-219.
56. Fatmi, A., Kim, T.K.E. Methods for enhancing the release and absorption of water insoluble active agents. WO2010075065 (2010).
57. Dunbar C. Dry powder formulations for inhalation. Drug Deliv Syst Sci 2002; 2(3): 78-80.
58. Fulton, J.L.D. Electrostatic deposition of particles generated from rapid expansion of supercritical fluid solutions. WO03101624 (2002).
59. Krukonis, P.M., Coffey, M.P. Gas anti-solvent recrystallization process. US5360478 (1991).
60. Hanna, M.Y.P. Method and apparatus for the formation of particles. WO9501221 (1995).
61. Ru, J.Q.L., Wei, W., Baoyou, Z., Lin, Z., Xiaonan, Z., Xiuhua, Z., Baishi, Z., Chunlin, Z., Yuangang, Z. Preparation method for supercritical anti-solvent of water-soluble nano glycyrrhizic acid powder. CN101756905 (2010).
62. th Forum of Pharmaceutical Sciences, Spa, Belgium 2007.
63. Weidner E. Process for the production of particles or powders. Brevet 1997.
64. Weidner E, Knez Z, Novak Z. PGSS (Particles from gas saturated solutions)- a new process for powder generation. In: Strasbourg, France 1994; 229-35.
65. Weidner E, Petermann M, Knez Z. Multifunctional composites by high-pressure spray processes. Curr Opin Solid State Mat Sci 2003; 7(4-5): 385-90.
66. Choi JA, Jung II, Lim GB, Ryu JH. Preparation of drug-loaded polymeric particles using a PGSS process and their characterization. J Biosci Bioengin 2009; 108: S26.
67. th Int Symp Supercrit Fluids, Versailles, France, 2003.
68. Fages J, Lochard H, Letourneau JJ, Sauceau M, Rodier E. Particle generation for pharmaceutical applications using supercritical fluid technology. Powder Technol 2004; 141(3): 219-26.
69. Garcia-Gonzalez CA, Argemi A, de Sousa ARS, Duarte CMM, Saurina J, Domingo C. Encapsulation efficiency of solid lipid hybrid particles prepared using the PGSS (R) technique and loaded with different polarity active agents. J Supercrit Fluids 2010; 54(3): 342-7.
70. Mandzuka Z, Knez Z. Influence of temperature and pressure during PGSS (TM) micronization and storage time on degree of crystallinity and crystal forms of monostearate and tristearate. J Supercrit Fluids 2008; 45(1): 102-111.
71. Martin A, Weidner E. PGSS-drying: Mechanisms and modeling. J Supercrit Fluids 2010; 55(1): 271-81.
72. Salmaso S, Elvassore N, Bertucco A, Caliceti P. Production of solid lipid submicron particles for protein delivery using a novel supercritical gas-assisted melting atomization process. J Pharm Sci 2009; 98(2): 640-50.
73. Malcolmson RJ, Embleton JK. Dry powder formulations for pulmonary delivery. Pharmaceut Sci Technol Today 1998; 1(9): 394-98.
74. Mehnert W, Mader K. Solid lipid nanoparticles - Production, characterization and applications. Adv Drug Deliv Rev 2001; 47(2-3): 165-96.
75. Demirel M, Yazan Y, Muller RH, Kilic F, Bozan B. Formulation and in vitro-in vivo evaluation of piribedil solid lipid micro- and nanoparticles. J Microencapsul 2001; 18(3): 359-71.
76. Giannola LI, Di Stefano V, De Caro V. White beeswax microspheres: A comparative in vitro evaluation of cumulative release of the anticancer agents fluorouracil and ftorafur. Pharmazie 1993; 48(2):123-26.
77. Yang S, Zhu J, Lu Y, Liang B, Yang C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res 1999; 16(5): 751-7.
78. Penkler LJ, Van Rooyen PH, Wessels PL. Conformational analysis of mu-selective [D-Ala2,MePhe4]enkephalins. Int J Peptide Protein Res 1993; 41(3): 261-74.
79. Zhang N, Ping Q, Huang G, Xu W, Cheng Y, Han X. Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int J Pharm 2006; 327(1-2):153-9.
80. Wang SL, Xie SY, Zhu LY, Wang FH, Zhou WZ. Effects of poly (lactic-co-glycolic acid) as a co-emulsifier on the preparation and hypoglycaemic activity of insulin-loaded solid lipid nanoparticles. IET Nanobiotechnol 2009; 3(4):103-8.
81. Reithmeier H, Herrmann J, Gopferich A. Lipid microparticles as parenteral controlled release device for peptides. J Control Release 2001; 73: 339-50.
82. Reithmeier H, Herrmann J, Gopferich A. Development and characterization of lipid microparticles as a drug carrier for somatostatin. Int J Pharmaceut 2001; 218: 133-43.
83. Liu W, Hu M, Xue C, Xu H, Yang X. Investigation of the carbopol gel of solid lipid nanoparticles for the transdermal iontophoretic delivery of triamcinolone acetonide acetate. Int J Pharmaceut 2008; 364(1): 135-41.
84. Priano L, Esposti D, Esposti R, Castagna G, De Medici C, Fraschini F, et al. Solid lipid nanoparticles incorporating melatonin as new model for sustained oral and transdermal delivery systems. J Nanosci Nanotechnol 2007; 7(10): 3596-601.
85. El-Kamel AH, Al-Fagih IM, Alsarra IA. Effect of sonophoresis and chemical enhancers on testosterone transdermal delivery from solid lipid microparticles: An in vitro study. Curr Drug Deliv 2008; 5(1): 20-6.
86. Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001; 47(2-3): 165-96.
87. Liu DF, Ge YF, Tang Y, Yuan YB, Zhang Q, Li R, Xu QW. Solid lipid nanoparticles for transdermal delivery of diclofenac sodium: Preparation, characterization and in vitro studies. J Microencapsulation 2010; 27(8): 726-34.
88. El-Kamel AH, Al-Fagih IM, Alsarra IA. Testosterone solid lipid microparticles for transdermal drug delivery. Formulation and physicochemical characterization. J Microencapsulation 2007; 24(5): 457-75.
89. Keck, C. Compositions containing lipid micro- or nanoparticles for the enhancement of the dermal action of solid particles. WO2010051918 (2010).
90. Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002; 54: S131-S155.
91. Borgia SL, Regehly M, Sivaramakrishnan R, Mehnert W, Korting HC, Danker K, et al. Lipid nanoparticles for skin penetration enhancement-correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. J Control Release 2005; 110(1): 151-63.
92. Weyenberg W, Filev P, Van den Plas D, Vandervoort J, De Smet K, Sollie P, et al. Cytotoxicity of submicron emulsions and solid lipid nanoparticles for dermal application. Int J Pharmaceut 2007; 337(1-2): 291-8.
93. Santos MC, Mehnert W, Schaller M, Korting HC, Gysler A, Haberland A, et al. Drug targeting by solid lipid nanoparticles for dermal use. J Drug Target 2002; 10(6): 489-95.
94. Wissing SA, Muller RH. The influence of solid lipid nanoparticles on skin hydration and viscoelasticity - in vivo study. Eur J Pharmaceut Biopharmaceut 2003; 56(1): 67-72.
95. Wissing SA, Muller RH. Cosmetic applications for solid lipid nanoparticles (SLN). Int J Pharmaceut 2003; 254(1): 65-8.
96. Wissing SA, Muller RH. The development of an improved carrier system for sunscreen formulations based on crystalline lipid nanoparticles. Int J Pharmaceut 2002; 242(1-2): 373-5.
97. Wissing SA, Muller RH. Solid lipid nanoparticles as carrier for sunscreens: In vitro release and in vivo skin penetration. J Control Release 2002; 81(3): 225-33.
98. Uner M, Wissing SA, Yener G, Muller RH. Skin moisturizing effect and skin penetration of ascorbyl palmitate entrapped in solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) incorporated into hydrogel. Pharmazie 2005; 60(10): 751-55.
99. Uner M, Wissing SA, Yener G, Muller RH. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for application of ascorbyl palmitate. Pharmazie 2005; 60(8): 577-82.
100. Yazan Y, Demirel M, Buyukkoroglu B, Selen KB. Solid lipid microparticle versus inclusion complex of piribedil. In: 2004/05//; Sevilla, Spain.
101. Jaspart S, Kirschvink N, Chiap P, Delattre L, Crommen J, Gustin P, et al. Solid lipid microparticles for administration by inhalation: optimisation of manufacturing parameters and preliminary tolerance study. Blankenberge, Belgium 2004.
102. Sanna V, Kirschvink N, Gustin P, Gavini E, Roland I, Delattre L, et al. Preparation and in vivo toxicity study of solid lipid microparticles as carrier for pulmonary administration. AAPS Pharm Sci Tech 2004; 5(2): e27.
103. Weers, J.G., Tarara, T.E., Dellamary, L.A., Riess, J.G., Schutt, E.G. Phospholipid-based powders for drug delivery. WO0185136 (2001).
104. Dellamary, L.A., Riess, J., Schutt, E.G., Weers, J.G., Tarara, T.E. Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use. WO0185137 (2001).
105. Morton, D.S.J. Dry powder composition comprising co-jet milled particles for pulmonary inhalation. EP2286797 (2011).
106. Choi HK, Kang KW, Chun MK, Kim O, Subedi RK, Ahn SG, et al. Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. Nanomed-Nanotechnol 2010; 6(2): 210-13.
107. Bondi ML, Craparo EF. Solid lipid nanoparticles for applications in gene therapy: A review of the state of the art. Exp Opin Drug Deliv 2010; 7(1): 7-18.
108. Brioschi AM, Calderoni S, Zara GP, Priano L, Gasco MR, Mauro A. Solid lipid nanoparticles for brain tumors therapy: state of the art and novel challenges. Nanoneuroscience Nanoneuropharmacol 2009; 180: 193-223.
109. Tabatt K, Kneuer C, Sameti M, Olbrich C, Muller RH, Lehr CM, et al. Transfection with different colloidal systems: Comparison of solid lipid nanoparticles and liposomes. J Control Release 2004; 97(2): 321-32.
110. Olbrich C, Bakowsky U, Lehr CM, Muller RH, Kneuer C. Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. J Control Release 2001; 77(3): 345-55.
111. Bondi ML, Azzolina A, Craparo EF, Lampiasi N, Capuano G, Giammona G, et al. Novel cationic solid-lipid nanoparticles as nonviral vectors for gene delivery. J Drug Target 2007; 15(4): 295-301.
112. Bondi ML, Craparo EF, Giammona G, Cervello M, Azzolina A, Diana P, et al. Nanostructured lipid carriers-containing anticancer compounds: Preparation, characterization, and cytotoxicity studies. Drug Deliv 2007; 14(2): 61-7.
113. Pilcer G. New highly effective dry powder tobramycin formulations for inhalation in the treatment of cystic fibrosis. Univ Libre de Bruxelles, Laboratoire de Pharmacie Galénique et de Biopharmacie institut de. Pharmacie 2008.
114. Souto EB, Wissing SA, Barbosa CM, Muller RH. Comparative study between the viscoelastic behaviors of different lipid nanoparticle formulations. J Cosmetic Sci 2004; 55(5): 463-71.
115. Cavallari C, Rodriguez L, Albertini B, Passerini N, Rosetti F, Fini A. Thermal and fractal analysis of diclofenac/Gelucire 50/13 microparticles obtained by ultrasound-assisted atomization. J Pharm Sci 2005; 94(5): 1124-34.
116. Pilaniya U, Pilaniya K, Chandrawanshi HK, Gupta N, Rajput MS. Formulation and evaluation of verapamil hydrochloride loaded solid lipid microparticles. Pharmazie 2011; 66(1): 24-30.
117. Hao J, Fang X, Zhou Y, Wang J, Guo F, Li F, Peng X. Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design. Int J Nanomed 2011; 6: 683-92.
118. Nayak AP, Tiyaboonchai W, Patankar S, Madhusudhan B, Souto EB. Curcuminoids-loaded lipid nanoparticles: novel approach towards malaria treatment. Colloids Surf B Biointerfaces 2010; 81(1): 263-73.
119. Rodriguez L, Passerini N, Cavallari C, Cini M, Sancin P, Fini A. Description and preliminary evaluation of a new ultrasonic atomizer for spray-congealing processes. Int J Pharm 1999; 183(2): 133-43.
120. Frederiksen HK, Kristensen HG, Pedersen M. Solid lipid microparticle formulations of the pyrethroid gamma-cyhalothrinincompatibility of the lipid and the pyrethroid and biological properties of the formulations. J Control Release 2003; 86: 243-52.
121. Dalpiaz A, Mezzena M, Scatturin A, Scalia S. Solid lipid microparticles for the stability enhancement of the polar drug N6- cyclopentyladenosine. Int J Pharm 2008; 355(1-2): 81-6.
122. Aji Alex MR, Chacko AJ, Jose S, Souto EB. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur J Pharm Sci 2011; 42(1-2): 11-18.
123. Bodmeier R, Wang J, Bhagwatwar H. Process and formulation variables in the preparation of wax microparticles by a melt dispersion technique. I. Oil-in-water technique for water-insoluble drugs. J Microencapsulation 1992; 9(1): 89-98.
124. Bodmeier R, Wang J, Bhagwatwar H. Process and formulation variables in the preparation of wax microparticles by a melt dispersion technique. II. W/O/W multiple emulsion technique for water-soluble drugs. J Microencapsulation 1992; 9(1): 99-107.
125. Yang R, Gao RC, Cai CF, Xu H, Li F, He HB, Tang X. Preparation of gel-core-solid lipid nanoparticle: a novel way to improve the encapsulation of protein and peptide. Chem Pharm Bull 2010; 58(9): 1195-202.
126. Reitz C, Strachan C, Kleinebudde P. Solid lipid extrudates as sustained-release matrices: the effect of surface structure on drug release properties. Eur J Pharmaceut Sci: Offic J Eur Federat Pharmaceutical Sci 2008; 35(4): 335-43.
127. Erni C, Suard C, Freitas S, Dreher D, Merkle HP, Walter E. Evaluation of cationic sold lipid microparticles as synthetic carriers for the targeted delivery of macromolecules to phagocytic antigen- presenting cells. Biomaterials 2004; 23: 4667-76.
128. Masters DB, Domb AJ. Liposphere local anesthetic timed-release for perineural site application. Pharmaceut Res 1998; 15(7): 1038-45.
129. Rodriguez L, Albertini B, Passerini N, Cavallari C, Giovannelli L. Hot air coating technique as a novel method to produce microparticles. Drug Dev Ind Pharm 2004; 30(9): 913-23.
130. Benita S, Zouai O, Benoit JP. 5-Fluorouracil: Carnauba wax microspheres for chemoembolization: An in vitro evaluation. J Pharm Sci 1986; 75(9): 847-51.
131. Demirel M, Yazan Y, Muller RH, Kilic F, Bozan B. Formulation and in vitro-in vivo evaluation of piribedil solid lipid micro - and nanoparticles. J Microencapsulation 2001; 18(3): 359-71.
132. Yener G, Incegul T, Yener N. Importance of using solid lipid microspheres as carriers for UV filters on the example octyl methoxy cinnamate. Int J Pharmaceut 2003; 258: 203-7.
133. Fang JY, Fang CL, Liu CH, Su YH. Lipid nanoparticles as vehicles for topical psoralen delivery: Solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm 2008; 70(2): 633-40.
134. Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: From concepts to clinic. Crit Rev Therapeut Drug Carrier Syst 2009; 26(6): 523-80.
135. Amighi, K., Sebti, T. Solid lipid particules as pharmaceutically acceptable fillers or carriers for inhalation. WO2006066367 (2006).
136. Marchaud, D.B. Anhydrous solid particles containing a lipid composition and pharmaceutical composition containing said particles. WO2006021709 (2006).
137. Lee, J.K. Lipid particles comprising bioactive agents, methods of preparing and uses thereof. WO2006068890 (2006).
138. Rachel JD, Lack EB, Larson B. Incidence of complications and early recurrence in 29 patients after facial rejuvenation with barbed suture lifting. Dermatol Surg 2010; 36(3): 348-54.
139. Charcosset, C.F. Novel method for preparing solid lipidic particles using a membrane reactor. WO2007000531 (2007).
140. Shekunov, B.Y.C., Huff, R.W. Method for producing solid-lipid composite drug particles. US2008286365 (2008).
141. Battaglia, L.S.T., Cavalli, R. Method for the preparation of solid lipid micro and nanoparticles. WO2008149215 (2008).
142. Vanderbist, F.B., Amighi, K., Pilcer, G. Improved pharmaceutical dry powder compositions for inhalation. WO2009050217 (2009).
143. Eskandar, F. Liposomal dispersion and dry powder formulations comprising oligonucleotides having improved downstream prossessing properties. WO2009027337 (2009).
144. Vassal, G.P., Ioulalen, K., Brun, B.C., Lassu, N. Galenic form under the form of solid lipid particles, useful in pediatrics, comprise temozolomide in lipid matrix, where the matrix comprises triglycerides with saturated fatty acids, and a mixture of fatty acids with specific fatty acids. FR2935270 (2010).
145. Bondi, M.L.G., Craparo, E.F., Drago, F. Nanostructured lipid carriers containing riluzole and phamaceutical formulations containing said particles. US2010247619 (2010).
146. Baker, T.S.W., Catterall, C.F., Eaton, M.A., Norman, T.J., Parker, D. Targeted lipid particles. US7718157 (2010).
147. Galuska, P.E., Rasmussen, L.M. Processes for producing lipid particles. US2010233344 (2010).
148. Brito, L.C., Ge, Q., Treco, D. Dry powder compositions for rna influenza therapeutics. US2011077284 (2011).